Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Sailer V, Pauli C, Merzier EC, Mosquera JM, Beltran H, Rubin MA, et al. On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer Res. 2017;37(4):1569-1573.

Magro CM, Momtahen S, Harp J. The distinctive histopathology of hydralazine-associated ANCA positive vasculitis: in vivo demonstration of NETosis. Eur J Dermatol. 2017;27(1):91-92.

Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, et al. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer. 2017;17(1):494.

Ferraro RA, Ivanidze J, Margolskee E, Tsang H, Sconomiglio T, Jhanwar YS. Invasive granulomatous cryptococcal sinusitis in an adult with multiple myeloma. Clin Imaging. 2017;41:65-68.

Geyer JT, Tam W, Liu Y-, Chen Z, Wang SA, Bueso-Ramos C, et al. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017;30(9):1213-1222.

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, et al. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017;198(6):1269-1277.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.

Morgenstern P, Pisapia D, Ramakrishna R. Calvarial Plasmacytoma Mimicking Meningioma as the Initial Presentation of Multiple Myeloma. Cureus. 2017;9(3):e1126.

Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma. Cell Metab. 2017;26(6):817-829.e6.